Table of Content - Parkinsons Disease Therapeutics Market

Parkinson's disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms. Levodopa, Dopamine agonists, MAO-B inhibitors, and Anticholinergics are some of the medications used for the treatment of Parkinson’s disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson’s disease. It is useful in controlling the symptoms such as slow movements and stiff & rigid body parts. Medication allows the majority of patients to retain a high quality of life and surgery can help some people improve their symptoms. Parkinson's disease patients also observe decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinson’s disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc. a pharmaceutical company announced that it received the U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) Sublingual Film for the acute, intermittent treatment for OFF episodes (i.e. re-emergence or worsening of PD symptoms) in patients with Parkinson’s disease. KYNMOBI is available in different strengths such as 10mg, 15mg, 20mg, and 25mg.

Key features of the study:

This report provides an in-depth analysis of the global Parkinson’s disease therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Parkinson’s disease therapeutic market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., and Boehringer Ingelheim International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Parkinson’s disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global Parkinson’s disease therapeutic market

Detailed Segmentation:

Global Parkinson’s Disease Therapeutic Market, By Drug Class
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others
Global Parkinson’s Disease Therapeutic Market, By Route of Administration
- Oral
- Injectable
- Nasal
- Transdermal
- Others
Global Parkinson’s Disease Therapeutic Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Parkinson’s Disease Therapeutic Market, By Region:
- North America
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Drug Class
    - Levodopa
      - Dopamine agonists
      - MAO-B inhibitors
      - Anticholinergics
      - Others
  - By Route of Administration
    - Oral
    - Injectable
    - Nasal
    - Transdermal
    - Others
  - By Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Reddy’s Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Drug Class
  - Market Snippet, By Route of Administration
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
  - Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- - Market Dynamics
    - Drivers
    - Restraints
    - Market Opportunities
  - Impact Analysis
  - Recent Test Launches
  - Epidemiology
  - Merger, Acquisition, and Collaborations
  - Regulatory Scenario
  - Key Developments
  - PEST Analysis
Global Parkinsons Disease Therapeutics Market – COVID-19 Impact Analysis
- - Economic Impact
  - COVID-19 Epidemiology
  - Impact on Supply and Demand
Global Parkinsons Disease Therapeutics Market, By Drug Class, 2018– 2030, (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018–2030
  - Segment Trends
- Levodopa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
  - Segment Trends
- Dopamine agonists
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- MAO-B inhibitors
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Anticholinergics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2018–2030, (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018–2030
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Injectable
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Nasal
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Transdermal
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
- Others (Rectal, Sublingual, among Others)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
  - Segment Trends
Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2018–2030, (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018–2030
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Bn)
Global Parkinsons Disease Therapeutics Market, By Region, 2018–2030, (US$ Bn)
- Introduction
  - Market Share Analysis, 2023 and 2030 (%)
  - Y-o-Y Growth Analysis, 2018–2030
  - Segment Trends
- North America
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
    - U.S.
    - Canada
- Europe
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
    - China
    - India
    - Japan
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 –2030, (US$ Bn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 –2030, (US$ Bn)
  - `Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 –2030, (US$ Bn)
  - Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018–2030, (US$ Bn)
  - Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 –2030, (US$ Bn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - Teva Pharmaceutical Industries Ltd.*
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Novartis AG
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - GlaxoSmithKline Plc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - AbbVie Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Merck & Co., Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Zydus Cadila
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Dr. Reddy’s Laboratories
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Sun Pharmaceutical Industries Ltd.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Cipla Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Boehringer Ingelheim International GmbH
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Denali Therapeutics Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Biogen Inc.
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Prevail Therapeutics
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Eli Lilly and Company
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
  - Voyager Therapeutics
    - Company Overview
    - Product Portfolio
    - Key Highlights
    - Financial Overview
    - Strategies
Section
- References
- Research Methodology
- About us and Sales Contact

*Browse 39 market data tables and 23 figures on “Global Parkinsons Disease Therapeutics Market” – Global forecast to 2030

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE